The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex
To determine the safety and patient tolerance of UVAR Photopheresis System (extracorporeal photopheresis) in the Treatment of AIDS-Related Complex (ARC).
|Study Design:||Endpoint Classification: Safety Study
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex|
Treatment involves the patient ingesting 8-methoxsalen (8-MOP) by mouth approximately two hours prior to each photopheresis session. The photopheresis instrument will separate the patient's white blood cells and some plasma from other blood components and return the majority of blood components to the patient. The separated white blood cells and plasma will be exposed to UVA (Ultraviolet A) light while outside the body. The UVA light photoactivates the 8-MOP drug which is now located in the DNA of the collected cells. After this exposure, the patients photoactivated white blood cells will be returned to the patient by venous access.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002011
|United States, New Jersey|
|Morristown Memorial Hosp|
|Morristown, New Jersey, United States, 07962|